Search hospitals > California > Woodland Hills
Kaiser Permanente-Woodland Hills
Claim this profileWoodland Hills, California 91367
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
120 reported clinical trials
8 medical researchers
Summary
Kaiser Permanente-Woodland Hills is a medical facility located in Woodland Hills, California. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Kaiser Permanente-Woodland Hills is involved with conducting 120 clinical trials across 290 conditions. There are 8 research doctors associated with this hospital, such as Gary L. Buchschacher, Helen H. Moon, Eric C. McGary, and Ashraf R. Aziz.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Gary L. BuchschacherKaiser Permanente-Anaheim7 years of reported clinical research
Studies Colon Cancer
Studies Stomach Cancer
14 reported clinical trials
34 drugs studied
Helen H. MoonKaiser Permanente-Riverside8 years of reported clinical research
Studies Skin Cancer
Studies Bladder Cancer
14 reported clinical trials
24 drugs studied
Eric C. McGaryKaiser Permanente-Anaheim10 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
19 drugs studied
Ashraf R. AzizKaiser Permanente-Baldwin Park6 years of reported clinical research
Studies Cancer
Studies T-Lymphoblastic Leukemia/Lymphoma
11 reported clinical trials
31 drugs studied
Clinical Trials running at Kaiser Permanente-Woodland Hills
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Prostate Cancer
Skin Cancer
Lymphoma
Breast cancer
Cancer
Esophageal cancer
Stomach Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Kaiser Permanente-Woodland Hills?
Kaiser Permanente-Woodland Hills is a medical facility located in Woodland Hills, California. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. Kaiser Permanente-Woodland Hills is involved with conducting 120 clinical trials across 290 conditions. There are 8 research doctors associated with this hospital, such as Gary L. Buchschacher, Helen H. Moon, Eric C. McGary, and Ashraf R. Aziz.